Faculty profile

Michael Moser

Back to faculty

ProfessorGeneral SurgeryUniversity of Saskatchewan

Michael Moser

Professor

General Surgery

College of Medicine

University of Saskatchewan

Saskatoon, Saskatchewan, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
10 publications in the last five years, latest in 2025.
Senior (last) author on 2 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

177

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Google Scholar

Search on ResearchGate

iDORCID

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Saskatchewan profile.

Irreversible Electroporation (NanoKnife): Clinical program and research Pancreatic Cancer Immuno-oncology Kidney Transplantation Research in machine cold perfusion preservation of kidneys for transplant Organ donor awareness Medical Education Tumor Ablation Technologies Biomedical Engineering

Latest papers

CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses.
Cancer immunology, immunotherapy : CII · 2025
The 41BB-agonist potentiates the therapeutic efficacy of a combined irreversible electroporation ablation treatment of lung cancer by promoting unexpected CD8+CD103+ cDC1 and tissue-resident memory T cell responses.
Frontiers in immunology · 2025
Technical and Institutional Factors Affecting Specimen Adequacy and Complications in Ultrasound-guided Kidney Biopsy: A Retrospective Cohort Study.
Canadian journal of kidney health and disease · 2025 · senior author

All 20 publications

Latest funding

Uniting for Leading Indigenous and non-Indigenous Medical Instrumentation, Technology, Entrepreneurship, and Design (UnLIMITED) Training Program
NSERC · 2022 · Co-investigator
$741,917
The Saskatchewan First Nations and Métis Health and Wellness Research, Training, and Knowledge Mobilization Network (CIHR-NEIHR Centre)
CIHR · 2019 · Co-investigator
$3,500,000
The Saskatchewan First Nations and Métis Health and Wellness Research, Training, and Knowledge Mobilization Network (CIHR-NEIHR Centre)
CIHR · 2019 · Co-investigator
$1,500,000

All 4 grants and awards

20 publications.

CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses.

Wu Z, Yang Z, Iftikhar T, Groot G, Leary SC, Baniak N, Ahmed S, Bosch M, Moser M, Zhang W, Jiang J, Xiang J

Cancer immunology, immunotherapy : CII2025Open Access

DOI: 10.1007/s00262-025-04217-7 PMID: 41251836

The 41BB-agonist potentiates the therapeutic efficacy of a combined irreversible electroporation ablation treatment of lung cancer by promoting unexpected CD8+CD103+ cDC1 and tissue-resident memory T cell responses.

Fang C, Wu Z, Leary SC, Bai Y, Yu M, Baniak N, Ahmed S, Groot G, Moser M, Zhang W, Zhang B, Huang J, Ma H, Feng Y, Xiang J

Frontiers in immunology2025Open Access

DOI: 10.3389/fimmu.2025.1688281 PMID: 41194931

Technical and Institutional Factors Affecting Specimen Adequacy and Complications in Ultrasound-guided Kidney Biopsy: A Retrospective Cohort Study.

Murray S, Dumaine C, Wall C, Banerjee T, Barton J, Moser M

Canadian journal of kidney health and disease2025Senior author

DOI: 10.1177/20543581251336551 PMID: 40336686

Twelve tips: Using generative AI to create and optimize content for virtual patient simulations.

Moser M, Posel N, Ganescu O, Fleiszer D

Medical teacher2025First author

DOI: 10.1080/0142159x.2025.2501252 PMID: 40372387

Prognostic Factors in Patients Diagnosed with Gallbladder Cancer over a Period of 20 Years: A Cohort Study.

Toussi N, Daida K, Moser M, Le D, Hagel K, Kanthan R, Shaw J, Zaidi A, Chalchal H, Ahmed S

Cancers20243 citationsOpen Access

DOI: 10.3390/cancers16172932 PMID: 39272789

PATCH-DP: a single-arm phase II trial of intra-operative application of HEMOPATCH™ to the pancreatic stump to prevent post-operative pancreatic fistula following distal pancreatectomy

Bubis LD, Behman R, Roke R, Serrano PE, Khalil JA, Coburn NG, Law CH, Bertens K, Martel G, Hallet J

HPB202215 citationsOpen Access

DOI: 10.1016/j.hpb.2021.05.007

Early discontinuation of adjuvant chemotherapy in patients with early-stage pancreatic cancer correlates with inferior survival: A multicenter population-based cohort study.

Muhammadzai J, Haider K, Moser M, Chalchal H, Shaw J, Gardiner D, Dueck DA, Ahmed O, Brunet B, Iqbal M, Luo Y, Beck G, Zaidi A, Ahmed S

PloS one202211 citationsOpen Access

DOI: 10.1371/journal.pone.0263250 PMID: 35108323

Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience

Bhatti T, Moser M, Tan KT, Chalchal H, Souied O, Le D, Shaw J, Zaidi A, Gill D, Ahmed S

Journal of Gastrointestinal Cancer20224 citations

DOI: 10.1007/s12029-021-00634-w

Early Single-Center Experience With Irreversible Electroporation for Stage 2, 3, and 4 Pancreatic Adenocarcinomas.

Wall C, Ahmed S, Kabir R, Lim HJ, Iqbal M, Chalchal H, Domes T, Beck G, Luo Y, Ogaick M, Shaw J, Moser M

Pancreas20223 citationsSenior author

DOI: 10.1097/mpa.0000000000002127 PMID: 36607943

Systemic Therapy and Its Surgical Implications in Patients with Resectable Liver Colorectal Cancer Metastases. A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference.

Ahmed S, Bosma N, Moser M, Ahmed S, Brunet B, Davies J, Doll C, Dueck DA, Kim CA, Ji S, Le D, Lee-Ying R, Lim H, McGhie JP, Mulder K, Park J, Ravi D, Renouf DJ, Schellenberg D, Wong RPW, Zaidi A

Current oncology (Toronto, Ont.)20221 citationsOpen Access

DOI: 10.3390/curroncol29030147 PMID: 35323347

Uniting for Leading Indigenous and non-Indigenous Medical Instrumentation, Technology, Entrepreneurship, and Design (UnLIMITED) Training Program

Co-investigatorNSERC2022Collaborative Research and Training Experience

Principal investigators: Zhang, Wenjun WJ

Keywords: covid-19; design; entrepreneurship; hospital; indigenous kowledge; industry; innovation; manufacturing; medical device; perspective; system

$741,917

The Saskatchewan First Nations and Métis Health and Wellness Research, Training, and Knowledge Mobilization Network (CIHR-NEIHR Centre)

Co-investigatorCIHR2019Operating Grant: NEIHR - Saskatchewan

Principal investigators: Tait, Caroline L; Fleury, Norman; Friesen, Marg; Hansen-Gardiner, Terri; Kewistep, Gilbert; Pelly, Judy; Sauve, Ernest; Watson, Morely; Foulds, Heather; Graham, Holly A; Henry, Robert; Lambert, Simon; LaVallie, Carrie; Lovo, Stacey; McKinstry, Sheri; Oosman, Sarah N; Sasakamoose, JoLee; Schindel, Joel; Skinner, Stuart J; Swidrovich, Jaris P

Keywords: Community-Engaged Research; Cultural Safety; Data Governance; First Nations Health; Indigenous Student Mentorship; Knowledge Translation; Metis Health; Rural And Remote Health; Treaty Right To Health; Truth And Reconciliation

$3,500,000

The Saskatchewan First Nations and Métis Health and Wellness Research, Training, and Knowledge Mobilization Network (CIHR-NEIHR Centre)

Co-investigatorCIHR2019Operating Grant: NEIHR - Consortium NEIHR Grant

$1,500,000

Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.

Co-investigatorCIHR2018Project Grant

Principal investigators: Ahmed, Shahid

Keywords: Biomarkers; Chemotherapy; Liver Metastases; Metastasectomy; Metastatic Colorectal Cancer; Pet Scan; Quality Of Life; Survival

$100,000

From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Michael Moser

Research

Latest papers

Latest funding

CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses.

The 41BB-agonist potentiates the therapeutic efficacy of a combined irreversible electroporation ablation treatment of lung cancer by promoting unexpected CD8+CD103+ cDC1 and tissue-resident memory T cell responses.

Technical and Institutional Factors Affecting Specimen Adequacy and Complications in Ultrasound-guided Kidney Biopsy: A Retrospective Cohort Study.

Twelve tips: Using generative AI to create and optimize content for virtual patient simulations.

Prognostic Factors in Patients Diagnosed with Gallbladder Cancer over a Period of 20 Years: A Cohort Study.

PATCH-DP: a single-arm phase II trial of intra-operative application of HEMOPATCH™ to the pancreatic stump to prevent post-operative pancreatic fistula following distal pancreatectomy

Early discontinuation of adjuvant chemotherapy in patients with early-stage pancreatic cancer correlates with inferior survival: A multicenter population-based cohort study.

Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience

Early Single-Center Experience With Irreversible Electroporation for Stage 2, 3, and 4 Pancreatic Adenocarcinomas.

Systemic Therapy and Its Surgical Implications in Patients with Resectable Liver Colorectal Cancer Metastases. A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference.

Uniting for Leading Indigenous and non-Indigenous Medical Instrumentation, Technology, Entrepreneurship, and Design (UnLIMITED) Training Program

The Saskatchewan First Nations and Métis Health and Wellness Research, Training, and Knowledge Mobilization Network (CIHR-NEIHR Centre)

The Saskatchewan First Nations and Métis Health and Wellness Research, Training, and Knowledge Mobilization Network (CIHR-NEIHR Centre)

Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.

Frequent collaborators

Shahid Ahmed

Adnan Zaidi

Wenjun Zhang

Haji Chalchal

Jim Xiang

Yigang Luo

Gary Groot

Tamalina Banerjee

Dorie-Anna Dueck

Scot Leary

Kamal Haider

Andrew Freywald

Mark Bosch

Mussawar Iqbal

Osama Ahmed

Rani Kanthan

Yue Wu

Kenneth Leslie

Douglas Quan

Anton Skaro

Christina Kim

Sulaiman Nanji

Erick McNair

Pablo Serrano Aybar

Kimberly Hagel

Michael Joseph Marcaccio